Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

101. The Effect of Extended Injection of Subcutaneous Heparin on Pain Intensity and Bruising Incidence Full Text available with Trip Pro

The Effect of Extended Injection of Subcutaneous Heparin on Pain Intensity and Bruising Incidence Reducing patients' pain is one of the main goals of providing clinical services, which requires nursing skill. As a simple technique, increasing the duration of subcutaneous heparin injection may affect the intensity of pain and bruising.The aim of this study was to assess the effect of increasing the heparin injection time on pain intensity and bruising associated with subcutaneous injection.The (...) present quasi-experimental study consisted of 86 patients, admitted to our hospital, who were treated with subcutaneous heparin injection. A McGill pain intensity questionnaire was used to measure pain severity in a purposive sampling. All of the subjects received subcutaneous heparin twice for 10 seconds. They also were injected twice with heparin infusion, although it was for 30 seconds this time. The interval between the two injections was 24 h, and the intensity of the pain was measured after each

2016 Electronic physician

102. Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children: A systematic review Full Text available with Trip Pro

Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children: A systematic review Around the world, guidelines and clinical practice for the prevention of complications associated with central venous catheters (CVC) vary greatly. To prevent occlusion, most institutions recommend the use of heparin when the CVC is not in use. However, there is debate regarding the need for heparin and evidence to suggest (...) normal saline may be as effective. The use of heparin is not without risk, may be unnecessary and is also associated with increased costs.To assess the clinical effects (benefits and harms) of heparin versus normal saline to prevent occlusion in long-term central venous catheters in infants, children and adolescents.A Cochrane systematic review of randomised controlled trials was undertaken.The Cochrane Vascular Group Specialised Register (including MEDLINE, CINAHL, EMBASE and AMED) and the Cochrane

2016 EvidenceUpdates

103. Heparin for the prevention of intraventricular haemorrhage in preterm infants. Full Text available with Trip Pro

Heparin for the prevention of intraventricular haemorrhage in preterm infants. Preterm birth remains the major risk factor for the development of intraventricular haemorrhage, an injury that occurs in 25% of very low birth weight infants. Intraventricular haemorrhage is thought to be venous in origin and intrinsic thromboses in the germinal matrix are likely to play a triggering role. Heparin activates antithrombin and promotes the inactivation of thrombin and other target proteinases (...) . The administration of anticoagulants such as heparin may offset the increased risk of developing intraventricular haemorrhage and may also reduce the risk of developing parenchymal venous infarct, a condition known to complicate intraventricular haemorrhage.To assess whether the prophylactic administration of heparin reduces the incidence of germinal matrix-intraventricular haemorrhage in very preterm neonates when compared to placebo, no treatment, or other anticoagulants.We searched the Cochrane Central

2016 Cochrane

104. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis

Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2016 PedsCCM Evidence-Based Journal Club

105. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty (Abstract)

Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty This prospective study was conducted to report the effect of oral factor Xa inhibitor and low-molecular-weight heparin (LMWH) on surgical complications following total hip arthroplasty (THA). The patients with an age < 60 years were randomly assigned to three groups (rivaroxaban, enoxaparin, and placebo) and the patients with an age ≥ 60 years were assigned to two

2016 EvidenceUpdates Controlled trial quality: uncertain

106. Bivalirudin versus heparin in high-risk patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Bivalirudin versus heparin in high-risk patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

107. Randomised controlled trial: Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer

Randomised controlled trial: Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer Article Text Therapeutics

2016 Evidence-Based Medicine

108. Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis

Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

109. Bivalirudin versus heparin in high bleeding risk patients: a meta-analysis of randomized controlled trials

Bivalirudin versus heparin in high bleeding risk patients: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2016 PROSPERO

110. Efficacy and safety of bivalirudin versus heparin plus routine use of GP Ilb/IIIa inhibitors in patients undergoing percutaneous coronary intervention: a meta analysis of randomized controlled trials and observation studies

Efficacy and safety of bivalirudin versus heparin plus routine use of GP Ilb/IIIa inhibitors in patients undergoing percutaneous coronary intervention: a meta analysis of randomized controlled trials and observation studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any

2016 PROSPERO

111. Pharmacokinetics and pharmacodynamics of heparin in pregnancy: a systematic review and meta-analysis

Pharmacokinetics and pharmacodynamics of heparin in pregnancy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2016 PROSPERO

112. Use of heparin bonded grafts in angioaccess: a review and meta analysis

Use of heparin bonded grafts in angioaccess: a review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

113. Heparin for the treatment of thrombosis in preterm and term neonates [Cochrane Protocol]

Heparin for the treatment of thrombosis in preterm and term neonates [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

114. An individual patient data meta-analysis of low molecular weight heparin for prevention of placenta-mediated pregnancy complications (AFFIRM)

An individual patient data meta-analysis of low molecular weight heparin for prevention of placenta-mediated pregnancy complications (AFFIRM) Untitled Document PROSPERO will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2016 PROSPERO

115. Meta-analysis of bypass surgery with heparin-bonded grafts for chronic lower limb ischaemia

Meta-analysis of bypass surgery with heparin-bonded grafts for chronic lower limb ischaemia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

116. Bivalirudin versus unfractionated heparin for patients undergoing percutaneous coronary intervention via radial approach: a meta-analysis of randomized trials

Bivalirudin versus unfractionated heparin for patients undergoing percutaneous coronary intervention via radial approach: a meta-analysis of randomized trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2016 PROSPERO

117. Bivalirudin versus Heparin with or without Glycoprotein IIb/IIIa Inhibitors in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised trials

Bivalirudin versus Heparin with or without Glycoprotein IIb/IIIa Inhibitors in patients with ST-segment elevation myocardial infarction: a meta-analysis of randomised trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2016 PROSPERO

118. Intermediate dose low-molecular-weight heparin for thromboprophylaxis: a systematic review with meta-analysis and trial sequential analysis

Intermediate dose low-molecular-weight heparin for thromboprophylaxis: a systematic review with meta-analysis and trial sequential analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

119. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Full Text available with Trip Pro

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Sickle cell disease is one of the most common and severe genetic disorders in the world. It can be broadly divided into two distinct clinical phenotypes characterized by either haemolysis or vaso-occlusion. Pain is the most prominent symptom of vaso-occlusion, and hypercoagulability is a well-established pathogenic phenomenon in people with sickle cell disease. Low-molecular-weight heparins (...) might control this hypercoagulable state through their anticoagulant effect. This is an update of a previously published version of this review.To assess the effects of low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches. We also searched abstract books of conference

2015 Cochrane

120. Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines

Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines | CADTH.ca Find the information you need Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines (...) Published on: November 24, 2015 Project Number: RB0937-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the appropriate dose of heparin required to maintain patency of peripherally inserted central catheters (PICC) for neonatal patients? Key Message No relevant literature was identified regarding the appropriate dose of heparin required to maintain patency of peripherally inserted central catheters

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review